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Abstract: Background: In response to COVID-19, the UK National Health Service (NHS) extended
influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21
season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate
all with a quadrivalent cell-based vaccine (QIVc) compared to returning to an at-risk only policy
after the pandemic resolves. Methods: A dynamic transmission model, calibrated to match infection
data from the UK, was used to estimate the clinical and economic impact of vaccination across
10 influenza seasons. The base case effectiveness of QIVc was 63.9% and the list price was GBP 9.94.
Results: Vaccinating 50% of all 50- to 64-year-olds with QIVc reduced the average annual number of
clinical infections (−682,000), hospitalizations (−5800) and deaths (−740) in the UK. The base case
incremental cost per quality-adjusted life-year gained (ICER) of all compared to at-risk only was
GBP6000 (NHS perspective). When the cost of lost productivity was considered, vaccinating all 50-
to 64-year-olds with QIVc became cost-saving. Conclusion: Vaccinating all 50- to 64-year-olds with
QIVc is likely to be cost-effective. The NHS should consider continuing this policy in future seasons.
Keywords: influenza vaccine; cost-effectiveness; economic modeling
1. Introduction
In the United Kingdom (UK), seasonal influenza vaccines have been provided annually
to those in a clinical risk group as well as those aged 65 years and above since 2000 [1]. The
clinical risk groups considered to be at higher risk of morbidity and mortality associated
with an influenza infection include those with chronic respiratory disease, chronic heart
disease, chronic kidney disease, chronic liver disease, chronic neurological disease, diabetes,
immunosuppression, asplenia or dysfunction of the spleen, and morbid obesity, as well as
pregnant women. While annual coverage for those 65 years and over from the 2007/08
to 2016/17 seasons has averaged 73% in England, the average coverage amongst at-risk
groups excluding pregnant women has been lower at 49% [1]. In 2011, the Joint Committee
on Vaccination and Immunisation (JCVI) recommended expansion of routine vaccination to
healthy or low risk individuals aged 2 to 16 years because it was likely to be a cost-effective
intervention [2]. Modeling predicted that routine vaccination would prevent disease in
the vaccinated individuals and indirectly prevent cases in other age groups by reducing
transmission [3].
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For the 2020/21 season, the National Health Service (NHS) extended the influenza
program to all individuals aged 50 to 64 years to support the health and care system given
the co-circulation of influenza and COVID-19 [4]. The objective of this research is to deter-
mine the cost-effectiveness of continuing to provide quadrivalent influenza mammalian
cell-based vaccine (QIVc) vaccinations to all individuals aged 50 to 64, including low and
at-risk people, once the COVID-19 pandemic has resolved.
2. Methods
2.1. Overview
A compartmental transmission model with a Susceptible–Exposed–Infectious–Recovered
(SEIR) structure was used to predict the number of influenza infections and their conse-
quences in the population of the United Kingdom. The dynamic model and the calibration
of the model inputs are described in the File S1. All individuals with symptomatic infec-
tions, which are also called clinical infections, are subdivided into cases that require no
care, cases that require outpatient only care, and cases that require hospitalization. While
deaths from influenza do occur in the community, it was conservatively assumed for this
analysis that all deaths occur amongst hospitalized cases only.
2.2. Comparators
A “current coverage”, or at-risk only, scenario was constructed using vaccine uptake
inputs from a previously published analysis (Table 1) [5]. This scenario was compared to
each of the scenarios displayed in Table 1, in which low risk 50- to 64-year-olds are also
vaccinated with QIVc at varying coverage levels. The coverage rate is uncertain, but it is
expected to be less than that seen among persons 65 years and over. Therefore, several
scenarios were run, assuming 40%, 50%, and 60% coverage of the low risk group. Coverage
of the vaccine in the at-risk group was 48.6% in the “current coverage” scenario. This was
adjusted upwards for the 50% and 60% scenarios so that coverage of the at-risk group was
at least equivalent to that of the low risk group.
Table 1. Vaccine coverage for the strategies compared in the analysis.
Age Group
Current Strategy (Reference) 40% (50 to 64 Years) 50% (50 to 64 Years) 60% (50 to 64 Years)
Low Risk At-Risk Low Risk At-Risk Low Risk At-Risk Low Risk At-Risk
6–23 months 0.10% 3.10% * * * * * *
2–6 years 28.10% 48.60% * * * * * *
7–17 years 27.60% 48.60% * * * * * *
18–49 years 0.00% 48.60% * * * * * *
50–54 years 0.00% 48.60% 40% * 50% 50% 60% 60%
55–59 years 0.00% 48.60% 40% * 50% 50% 60% 60%
60–64 years 0.00% 48.60% 40% * 50% 50% 60% 60%
65–74 years 68.00% 68.00% * * * * * *
75 years and above 80.00% 80.00% * * * * * *
* Same as the current or reference strategy.
2.3. Vaccine Effectiveness
The vaccines given to each age group were chosen to reflect the JCVI-recommended
and NHS-funded vaccines for the 2021/22 season [6–8]. In this analysis, individuals aged
18 to 64 years old receive a quadrivalent influenza cell-based vaccine (QIVc) as this is one
of the vaccines that is both recommended by the JCVI and funded by the NHS for this
age group. QIVc is a version of influenza vaccine that is cultured in mammalian cells
in order to avoid viral adaptations that reduce the match to the recommended strains
that may occur in the vaccines produced in eggs. Most data on the effectiveness of this
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vaccine come from the use of the vaccines in the United States, starting in the 2017/18
season [9–14]. The effectiveness of all influenza vaccines varies by season and depends
in part on the degree to which the vaccine strains, which are determined annually by the
World Health Organization, [15] match the strains that are circulating locally. Therefore,
effectiveness may vary by season and location. For this analysis, the effectiveness of QIVc
was estimated based on the latest Public Health England (PHE) data from the UK during
the 2019/20 season. PHE collected data from five primary care influenza sentinel swabbing
surveillance schemes to conduct a test-negative case control study of vaccine effectiveness
in this season [16]. They reported the effectiveness of QIVc against all influenza types
amongst 18- to 64-year-olds, adjusted for confounders, to be 63.9% (95% confidence interval
of 26.9% to 82.2%). This effectiveness estimate was used for the base-case analysis, with
scenario analyses conducted using the upper and lower bounds of the 95% confidence
interval estimates.
The vaccines used in the age groups not targeted for this analysis were also determined
based upon the 2021/22 NHS recommendations for influenza vaccines [6,7]. Children aged
6 to 23 months received quadrivalent influenza egg-culture vaccine (QIVe), while 2- to
17-year-olds received quadrivalent live-attenuated influenza vaccine (QLAIV). Individuals
ages 65 years and above received adjuvanted quadrivalent inactivated vaccine (aQIV). The
effectiveness of each of these vaccines is described in the File S1.
2.4. Costs
The analyses were conducted using both the cost perspective of the NHS and Personal
Social Services, as recommended by the National Institute for Health and Care Excellence
(NICE) [17], and a societal perspective that includes productivity losses. The unit cost
for QIVc was assumed to be GBP 9.94, QIVe GBP 8.97, QLAIV GBP 18.00, and aQIV GBP
11.88 [18]. The unit cost for QIVe is an average of the NHS list prices for the multiple
funded QIVe formulations. Vaccine administration was assigned a cost of GBP 10.06 per
dose based on the directed enhanced service payments for the seasonal influenza program
(2020/21) for general practitioners [19].
Many of the symptomatic influenza cases receive no medical care. As in previous UK
analyses, [20,21] only 10% of infections were assumed to receive outpatient care and these
were assigned the average age-specific costs displayed in Table 2. This cost from Pitman
and colleagues, [22] inflated to 2020 values [23], included the cost of consultations and
some medications. The cost of anti-viral treatment [24] was also added as recommended
by UK guidelines [25] based on previously published UK analyses [26]. The age- and
risk-group specific probability of hospitalization rates given clinical infection (Table 2)
were derived using an analysis of UK data by Cromer and colleagues as described in the
File S1 [27]. Costs per admission (Table 2) were also from Pitman and colleagues [22]. The
case fatality rates for hospitalized cases (Table 2) were taken directly from Cromer and
colleagues [27].
For the societal perspective, all NHS and PSS costs plus the cost of time lost from work,
estimated using the human capital method, were included. For the base case, the average
time loss per working person developing a case of influenza was assumed to be 4.0 days
based on data from a study of individuals with laboratory confirmed influenza cases in
France [28,29]. The proportion working (Table 2) was estimated by age group based on UK
data [30]. The daily wage was estimated as GBP 114.75 based on a UK annual survey [30].
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Low Risk At-Risk Low risk At-Risk Low Risk (GBP)
At-Risk
(GBP)
6–23 months 1,551,398 −0.2% 4.9% 3.59% 3.16% 0.43 17.45 GBPGBP94.35 GBP98.36 GBP1985.33 0%
2–6 years 4,009,154 −0.2% 7.3% 2.72% 3.46% 0.43 17.45 GBPGBP74.73 GBP80.74 GBP1985.33 0%
7–17 years 8,621,803 0.6% 9.6% 0.16% 1.03% 0.74 24.43 GBP76.24 GBP84.25 GBP2006.59 3.92%
18–49 years 27,477,085 0.1% 9.1% 0.19% 1.18% 6.07 39.97 GBP104.07 GBP106.55 GBP2053.65 80.54%
50–59 years 9,062,377 −0.8% 18.3% 0.54% 3.25% 6.07 39.97 GBP124.51 GBP126.99 GBP2451.38 72.40%
60–64 years 3,757,250 2.1% 18.3% 0.60% 3.61% 6.07 39.97 GBP124.51 GBP126.99 GBP2451.38 72.40%
65–74 years 6,694,529 1.1% 45.0% 3.12% 5.69% 185.29 428.52 GBP125.35 GBP125.35 GBP6618.61 10.80%
75 years and above 5,693,825 2.9% 45.0% 3.15% 5.75% 185.29 428.52 GBP125.35 GBP125.35 GBP6618.61 10.80%
Source [31] [31] [3,32,33] [27] [27] [27] [27] [22,24,25] [22,24,25] [22] [30]
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2.5. Utilities
A quality-adjusted life years (QALYs) decrement, or a disutility weighted by time
spent in the health state, was applied to cases of influenza as in previous UK analyses.
A decrement of 0.0075 [3,34] was applied to uncomplicated cases of influenza based on
individuals with influenza-like illness, and 0.0180 was applied to hospitalized cases based
on individuals with inpatient pneumococcal disease [3,35]. The discounted number of
QALYs lost due to death from influenza was calculated using expected survival [36] and
expected age-specific utility values [37]. QALYs lost due to death in the low and at-risk
groups differ, as individuals in the at-risk groups have comorbidities that result a lower
quality-adjusted life expectancy compared to low risk individuals in the same age group.
However, because the distribution of comorbidities in the target population is unknown, it
was not possible to develop separate estimates of QALYs lost to death in the at-risk and low
risk groups. Instead, we conducted a sensitivity analyses where we reduced the mortality
rate in low risk individuals to see if having a differential impact of mortality by risk group
would impact our results.
2.6. Analysis
The model was run for 10 seasons, but all outcomes are presented as averages per
season over the 10 years. The size of the population in Year 1 of the simulation was based
on 2019 data and then assumed to change according to the average growth rate from
the Office for National Statistics (Table 2) [31]. The proportions of at-risk individuals
due to complications was based on data presented in previously published UK analyses
(Table 2) [3,32,33]. A discount rate of 3.5% for both costs and outcomes was used in line
with NICE recommendations [17].
As described above, scenario analyses were conducted using multiple vaccine cov-
erage and QIVc effectiveness estimates. In addition, deterministic sensitivity analyses
(DSAs) with key variables were conducted to determine their impact on the incremental
cost-effectiveness ratio (ICER) (NHS cost perspective). These analyses were run assuming
50% coverage and 63.9% effectiveness of QIVc. For example, the hospitalization rates
were varied from 50% to 200% of the base case values in order to represent the variation
in severity of the influenza epidemic across seasons [16,38]. Varying the hospitalization
rates also varies the number of deaths due to influenza that occur. PHE has estimated
that the numbers of deaths attributable to influenza have varied substantially over the last
5 years [16]. The QALY decrement for uncomplicated and complicated cases was varied
from 0.0002 and 0.0146, respectively, to 0.0271 and 0.0217, respectively. These ranges were
based on the 95% confidence interval estimated in the source publication [3]. In addition,
the QALY decrement associated with death due to influenza was considered by varying the
base-case age-specific utility values by 10%. As described above, the mortality rate in low
risk individuals was reduced by 50% to determine if having a differential QALY loss with
death by risk group impacts the results. Finally, the discount rate for costs and outcomes
was also reduced to 1.5%, as in its recent methods review NICE has acknowledged that
‘the evidence suggests there is a case to change the reference discount rate to 1.5% per year
for both costs and effects’ [39].
For the societal perspective, the amount of time lost from work was varied in DSAs.
Time lost from work due to influenza was varied from 1.2 to 6.8 days based on the standard
deviation of time loss from work in Carrat et al. [29] In addition, scenario analyses assuming
that all working individuals need to take 1 h off work in order to be vaccinated (thereby
adding to the cost of vaccine administration) were conducted.
Probabilistic sensitivity analyses were conducted by varying the inputs to the eco-
nomic model—including percent of patients seeking a medical care visit, inpatient complica-
tions, outpatient complications, influenza-related mortality rates, QALYs lost for infections
with inpatient complications, and QALYs lost for infections with no complications—using
the distributions described in the File S1.
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3. Results
3.1. Base Case Analysis
When vaccination with QIVc is extended from an at-risk only strategy to all individuals
aged 50 to 64 years, the morbidity and mortality associated with influenza decreases.
As shown in Table 3, the impact depends upon vaccine coverage, but, in general, the
numbers of clinical infections, hospitalizations and deaths decrease as the number of
vaccinations of individuals aged 50 to 64 years increases. While there is a direct benefit to
the 50- to 64-year-olds themselves, the model predicts that more morbidity and mortality
is prevented in the other age groups through a reduction in transmission. For example,
with 50% coverage, a reduction of about 1200 hospitalizations annually is seen in the 50- to
64-year-olds, while a reduction in 4600 hospitalizations is seen in other age groups. The
results by age group are presented in the File S1 (Table S6).
Table 3. Base case results: the average annual change in clinical cases when low risk individuals ages













Vaccinations 16,140,518 4,198,394 5,280,907 6,565,605
Clinical Infection 2,615,577 −544,718 −682,036 −844,277
Hospitalizations 22,148 −4629 −5807 −7257
Deaths 2834 −588 −737 −916
Increasing the number of vaccinations results in a net cost to the NHS due to the
increased cost of the vaccine itself and vaccine administration, but, as shown in Table 4,
some of this cost is offset by reduction in treatment costs associated with infection. With 50%
coverage, the expected discounted cost of influenza (including vaccinations and treatment
of influenza cases) to the NHS over 10 seasons is approximately GBP 4.8 billion or an
average of GBP 480 million per year. This is more than the expected discounted cost of
the current program to the NHS—GBP 4.1 billion over 10 seasons or GBP 410 million per
year. However, by preventing illness and deaths, 6446 and 4483 discounted QALYS will be
gained, respectively, per year, for an annual total of 10,929 discounted QALYs gained. With
50% coverage of 50- to 64-year-olds, the average annual incremental NHS discounted cost
compared to the current strategy is GBP 66,000,000. The incremental cost per QALY gained
of vaccinating 50% of all 50- to 64-year-olds is therefore approximately GBP 6000 (Table 5).
While Table 4 shows that varying vaccine coverage between 40% and 60% does impact costs
and expected QALYs, the incremental cost-effectiveness ratio (ICER) of vaccinating low
risk 50- to 64-year-olds remains at approximately GBP 6000 per QALY gained irrespective
of coverage within this range (Table 5). The results by age group are presented in the
File S1 (Table S7).
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Table 4. Base case results: the average annual discounted costs and quality-adjusted life-years with different level of
coverage of low risk individuals aged 50 to 64 years old.
Current Strategy (0%







Cost of Vaccinations GBP 180,483,831 GBP 216,398,306 GBP 225,658,483 GBP 236,648,224
Cost of Vaccine Administration GBP 139,240,897 GBP 175,588,948 GBP 184,960,917 GBP 196,083,331
Cost of Medical Care Visits GBP 22,781,219 GBP 17,851,296 GBP 16,620,253 GBP 15,172,047
Cost of Hospitalizations GBP 71,397,019 GBP 56,329,214 GBP 52,517,054 GBP 47,893,573
Total NHS Costs GBP 413,902,966 GBP 466,167,764 GBP 479,756,707 GBP 495,797,175
Productivity GBP 538,666,193 GBP 418,970,603 GBP 389,271,255 GBP 354,455,465
Total Societal Costs GBP 952,569,159 GBP 885,138,367 GBP 869,027,961 GBP 850,252,641
QALYs 51,414,486 51,423,206 51,425,415 51,428,069
NHS—National Health Service; QALY—Quality-adjusted life-years.
Table 5. The incremental cost per quality-adjusted life-year ratio associated with vaccinating low risk individuals ages 50-
to 64-year-olds across various coverage and vaccine effectiveness levels.
Incremental Cost per QALY Gained Compared to the Current Strategy
Vaccine
Effectiveness
40% (50 to 64 Years) vs. Current 50% (50 to 64 Years) vs. Current 60% (50 to 64 Years) vs. Current
NHS Perspective
26.90% GBP 15,431 GBP 15,268 GBP 14,975
63.90% GBP 5993 GBP 6025 GBP 6029
82.20% GBP 4574 GBP 4661 GBP 4745
Societal Perspective
26.90% GBP 1642 GBP 1523 GBP 1337
63.90% Dominates * Dominates * Dominates *
82.20% Dominates * Dominates * Dominates *
* Dominates means that increased coverage of the low risk group is more effective and cost savings compared to no coverage. NHS—
National Health Service; QALY—Quality-adjusted life-years; vs.—versus.
When productivity costs are introduced into the analysis, each case of influenza pre-
vented leads to more societal savings which more than offset the NHS costs of vaccination.
The total societal costs decrease as the coverage of the 50- to 64-year-olds increases (Table 4).
For the base case, when considering a societal perspective, vaccinating the low risk group
provides both cost savings, due to productivity losses averted, and more QALYs regardless
of the coverage level and is therefore considered to be dominant (Table 5).
The DSAs summarized in the Tornado diagram in Figure 1 demonstrate that the ICER
(NHS perspective) is most sensitive to the effectiveness of the vaccine, as expected. If the
effectiveness of QIVc is as low as 26.9%, then the cost per QALY gained of vaccinating the
low risk group increases to GBP 15,000, but it may be as low as GBP 4700 if the vaccine is
82.2% effective. The results are next most sensitive to fluctuations in hospitalization rates,
which impact both the cost of influenza treatment and the number of deaths because all
deaths are assumed to come from hospitalized cases. When the rate of hospitalization is half
of what was assumed in the base case, the number of hospitalizations and deaths prevented
annually decrease from 5807 and 737 in the base case to 2903 and 368, respectively. When
the rate is doubled, the number of hospitalizations prevented increases to 11,614, while the
number of deaths prevented increases to 1474. These changes in influenza outcomes cause
the ICER to vary from GBP 2700 (high hospitalization) to GBP 9800 (low hospitalization).
Next, the ICER is most sensitive to variation in the QALY decrements associated with
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influenza cases: the ICER may range from GBP 2900 to GBP 9900 depending on the value
used within the range considered. Varying the discount rates, the coverage of the low risk
group, the baseline utility associated with the population, and changing the mortality in
the low risk group only have a minimal impact on the ICER.
Figure 1. Tornado diagram: impact of the deterministic sensitivity analyses on the incremental cost per quality-adjusted
life-year (NHS cost perspective) associated with vaccinating 50% of low risk individuals ages 50 to 64 years old.
The DSAs demonstrate that the productivity costs that are saved for the 50% vaccina-
tion coverage of 50- to 64-year-olds scenario, depend upon the average number of days lost
from work per case. If an average of 4 days is lost from work per case, there is a net saving
in total societal costs when implementing the strategy, regardless of whether time lost from
work due to seeking vaccination is assumed to be 0 or 1 h. If only 1.2 days are lost, the
gains in productivity do not offset the cost of vaccination, but implementation of the low
risk strategy is still cost-effective. From the societal perspective, the ICER is GBP 1900 per
QALY gained assuming 0 h of work time loss for vaccination and GBP 7200 assuming 1 h.
The detailed results from these sensitivity analyses are found in the File S1 (Table S8).
3.2. Probabilistic Sensitivity Analysis
A probabilistic sensitivity analysis was conducted using the base case effectiveness of
63.9% and also for the lower and upper 95% confidence interval values of 26.9% and 82.2%.
As shown in the File S1 (Figure S5), in 100% of the simulations, the ICER is below the
willingness-to-pay threshold of GBP 25,000 with an absolute vaccine effectiveness of 26.9%,
below GBP 10,000 for an effectiveness of 63.9% and below GBP 8000 for an effectiveness for
an effectiveness of 82.2%.
4. Discussion
Maintaining the 2020/21 influenza season policy of vaccinating low risk 50- to
64-year-olds is expected to decrease morbidity and mortality in the UK population and be
a cost-effective policy during a typical influenza season using QIVc. The total cost to the
NHS and the overall benefits will depend on the coverage achieved in this population, but
regardless, the ICER of vaccinating low risk 50- to 64-year-olds compared to not vaccinating
this sub-group is around GBP 6000 per QALY under base case assumptions. When the cost
of lost productivity is considered, the policy has the potential to be both more effective and
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cost-saving from the societal perspective. Overall, our analysis indicates that maintaining a
policy of vaccinating all 50- to 64-year-olds in the UK post-pandemic is cost-effective.
The burden of influenza illness varies substantially from season to season. For exam-
ple, PHE estimates that the number of deaths attributed to influenza in England at 3966
in the 2018/19 season and 22,087 in the 2017/18 season. There may be multiple reasons
for this variation, including vaccine effectiveness against the local circulating strains and
the virulence of the circulating strains. We conducted sensitivity analyses varying vaccine
effectiveness. The range used for vaccine effectiveness in sensitivity analyses was based
on the PHE test-negative design study, which is the preferred design for observational
studies of influenza vaccine effectiveness [40]. As recommended by Newell et al., [41]
this study uses the outcome of laboratory confirmed influenza and we assume that this
effectiveness can be applied equally to prevention of transmission, hospitalization and
deaths. Similar to many studies using laboratory confirmed influenza infections as the
outcome of interest, the 95% confidence interval from this study was wider than in the
database analyses focusing on medical encounters [42]. However, even when we used this
wide range in our DSAs, the ICER ranged from GBP 4700 to GBP 15,000 indicating that this
policy is likely to be cost-effective assuming a willingness-to-pay threshold of GBP 20,000
or greater.
We also conducted DSAs with variables that would reflect variation in influenza
virulence including hospitalization rates, case fatality, QALY decrement and time lost from
work. All of the variables had less of an impact on the ICER than varying the vaccine
effectiveness. Furthermore, in the PSAs for the various vaccine effectiveness levels, where
the variables representing the impact of influenza were systematically varied, the ICER
associated with implementing the strategy remained below GBP 25,000.
Assuming 50% coverage, offering the vaccine to the entire 50- to 64-year-old pop-
ulation, including those at low risk, would require approximately 5,300,000 additional
vaccinations annually. If vaccination is restricted to those age 55 to 64 years only, the number
of additional vaccinations required drops to 3,400,000. For the 60 to 64 age group, it de-
creases to 1,700,000. These age-varying strategies have almost identical ICERs (in technical
terms, they lie on a nearly linear section of the efficiency frontier) so the choice among
them might well be budget-driven.
4.1. Comparison to Previous Studies
In 2006, Turner et al. [43] published a cost-effectiveness analysis examining this issue
of extending immunization with a conventional egg-based trivalent influenza vaccine
in the UK to healthy adults aged 50–64 years. A static model was used, and therefore
the estimates did not include any of the indirect benefit (herd immunity) associated with
reducing the number of susceptible individuals in the population. The efficacy of the
vaccine in this age group was 69% in base case and varied from 55% to 79% in sensitivity
analyses. The cost of the vaccine was lower at GBP 7.24, but the costs associated with
health care treatment of influenza and time loss were also lower as they were in 2002 UK
prices. The base case ICER (NHS cost perspective) in that study was GBP 6174 per QALY
gained. The ICER using the societal cost perspective was higher at GBP 10,766 because they
assumed a 1-h time loss cost for the working individuals to receive an influenza vaccine for
their base case. Given the widespread influenza vaccination settings that are now available
in the UK, we assumed in the base case that individuals did not need to lose time from
work in order to be vaccinated. For the societal perspective, Turner et al. used a lower
estimate of average days lost per case of influenza (2.9 days) but a similar range to ours for
sensitivity analyses.
Newall et al. [41] reviewed multiple analyses that had been conducted using static
models looking at this research question in various countries and concluded that vaccina-
tion of all 50 to 64 years old is likely to be cost-effective. The results were most impacted
by the estimates of vaccine effectiveness and of the incidence of the serious outcomes
associated with influenza.
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In 2015, Baguelin et al. [3] considered the issue of expanding vaccination to healthy
individuals in various age groups, including the 50- to 64-year-olds, using a dynamic
model. Their analysis, like ours, therefore included benefits of reducing transmission to
other groups in society. They assumed a vaccine effectiveness of 70% for seasons in which
vaccines strains were well-matched to the circulating strain and 42% for poorly matched
seasons. Vaccine cost, including administration, was GBP 15.85. They estimated that
the ICER (NHS cost perspective) associated with expanding vaccination to healthy 50 to
64 years old on top of vaccinating as per what we refer to as the “current strategy”, was
GBP 8093 per QALY.
4.2. Limitations
As with any analysis based on modelling, there are a number of limitations associated
with this model. Influenza seasons are highly variable and our model is calibrated to match
only two rates of infections. As Newell et al. [41] commented, the severity of influenza
seasons was one of the important determinants of cost-effectiveness in past publications
analyzing vaccination of those aged 50 to 64 years of age. Influenza seasons are highly
variable and the dynamic model used in this analysis contained two different calibrated
seasons: one that was primarily type A and one that was a mix of types A and B. We did
not otherwise vary the number of clinical influenza infections predicted by the model,
but we did vary the proportions of hospitalizations and deaths associated with those
infections in sensitivity analyses. In addition, our model is conservative as we predict
2834 deaths in the UK in all age groups in an average season. Had we included estimates
of mortality due to influenza cases that are not hospitalized, this number would have
been higher. PHE has estimated that the number of influenza-attributable deaths have
been at least 3966 per season in England alone over the past five seasons [16]. As we
demonstrated in the sensitivity analyses, whenever the severity of influenza is increased,
the cost-effectiveness vaccinating all 50- to 64-year-olds increases. Therefore, our analysis
may underestimate the value associated with maintaining this policy.
While the model includes the most recent data available, several model inputs such
as contact matrices, influenza hospitalization rates and case fatality rates were based on
studies conducted prior to 2010. If influenza burden has changed over the last decade, the
model will not capture these variations in hospitalization or case fatality rates. Furthermore,
it is unclear whether the COVID-19 pandemic will impact the burden of influenza in the
future. It is possible, for example, that social distancing practices during the pandemic will
lead to post-pandemic changes in behavior that impact contact rates between individuals.
The mass vaccination campaign associated with COVID-19 may change adults’ willingness
to receive an annual influenza vaccine. Ultimately, any such long-term changes would
impact the transmission of influenza in the UK population. However, the direction of such
changes is still unclear.
A systematic review of studies of the impact of influenza on productivity reported
a large degree of heterogeneity in study methods and quality [28]. They reported that
mean time lost form work in studies of laboratory confirmed influenza varied from 1.5
to 4.9 days lost. In a more recent study of a community cohort of individuals in the UK
over severe seasons, 34% of the 62 employed individuals aged 16 years and above who
had PCR-confirmed influenza A reported taking an average of 4 days off work due to their
illness [44]. This implies an average of 1.4 working days lost for all of those employed.
The authors suggest that the estimate of days lost may be lower than reported in other
studies because they include milder cases that do not seek medical care. While this value
is lower than our base case value, it does fall within the range of the sensitivity analyses
that we conducted. We did not include caregiver time loss from work, as there are limited
data focusing on cases in children only [28]. This is a conservative approach because
including this cost would also add to the overall burden of lost productivity associated
with influenza [45]. Overall, for the age group under consideration, the potential savings
Vaccines 2021, 9, 598 11 of 13
in productivity costs associated with vaccination of this age group is important from a
societal perspective as the majority of individuals are working.
Finally, there is a lack of data on the impact of influenza on quality of life, with
several studies using estimates from studies of pneumonia patients. In the same study
of community-based influenza described above, Fragaszy et al. [44] also measured utility
and their findings suggest that the quality-of-life decrement may also be less than used
in past cost-effectiveness analyses. On the other hand, the impact on hospitalization and
serious respiratory disease on elderly individuals following hospital discharge may be
underestimated [46]. In our sensitivity analyses, we included a wide range of quality-of-life
decrements and still found vaccination of the low risk individuals to be cost-effective.
5. Conclusions
The UK government has decided to extend vaccination in order to protect the capacity
of the NHS due to the COVID-19 pandemic. Our analysis demonstrates that when consid-
ering influenza in isolation, continuing to vaccinate these individuals with QIVc in future
seasons is likely to be cost-effective from the perspective of the NHS and provide cost-
savings when lost productivity is considered. UK policy makers should consider continuing
this policy in future seasons once the concern over COVID-19 pandemic is mitigated.
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